THZ-P1-2

THZ-P1-2 is a small molecule pan-inhibitor of the Phosphatidylinositol-5-phosphate 4-kinase type 2 (PIP4K2) family, which includes the isoforms PIP4K2A, PIP4K2B, and PIP4K2C. It is a covalent inhibitor designed as a chemical probe to disrupt the generation of PIP 4,5P2, a critical secondary messenger in signal transduction and metabolic regulation. In preclinical models of Acute Myeloid Leukemia (AML), THZ-P1-2 has demonstrated potent anti-leukemic activity by inducing mitochondrial dysfunction and disrupting autophagy. Research indicates that high expression of PIP4K2 isoforms is associated with poor prognosis and resistance to standard therapies like venetoclax; THZ-P1-2 has shown synergistic potential when combined with venetoclax to enhance apoptosis and DNA damage in resistant leukemic cells.